Clinical Study

Keychain- Phase II Randomized Trial Of Radiotherapy With Concurrent And Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy In Patients With Advanced/Intermediate-Risk P16+ Head And Neck Squamous Cell Carcinoma

Posted Date: Apr 23, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to test the hypothesis that pembrolizumab improves progression free survival (PFS) in this population compared to standard of care (RT plus cisplatin)


To Be Eligible: Must Have Diagnoses Of Hnscc, Adequate Organ Function, No Prior Malignancy Within 3 Years, No Prior Therapy For Study Cancer, No Hypersensitivity To Study Drugs Or Excipients, No Active Severe Co-Morbidity


Head And Neck Cancer, Hnscc

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.